Anavex life sciences promotes walter e kaufmann, m.d. to chief scientific officer and appoints edward r hammond, m.d.

New york, jan. 06, 2022 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced that walter e kaufmann, m.d. has been promoted to chief scientific officer and edward r hammond, m.d., m.p.h., phd, has been appointed chief medical officer, effective immediately.
AVXL Ratings Summary
AVXL Quant Ranking